CAR NK Cells for B-Cell Cancers
Trial Summary
What is the purpose of this trial?
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, it mentions that recent use of any cancer-directed therapy within a specified window before the first dose of NKX019 is not allowed. It's best to discuss your current medications with the trial team.
What data supports the idea that CAR NK Cells for B-Cell Cancers is an effective treatment?
The available research shows that CAR NK Cells, specifically those targeting CD19, have demonstrated high effectiveness against B-cell cancers. In one study, these cells showed strong activity against cancer cells in laboratory settings, similar to CAR-T cells, but with fewer side effects. Another study highlighted that CAR NK cells could be produced efficiently and used as an 'off-the-shelf' treatment, making them more accessible. These findings suggest that CAR NK Cells are a promising and potentially safer alternative to other treatments like CAR-T cells for B-cell cancers.12345
What safety data exists for CAR NK cell treatment for B-cell cancers?
CAR NK cells, including those targeting CD19, have shown a safer clinical profile compared to CAR-T cells, with no risk of graft-versus-host disease. Preclinical studies and early clinical trials indicate that CAR NK cells have potent antileukemic activity with a lower toxicity profile. The safety and efficacy of allogeneic cord blood-derived CD19 CAR-NK cell therapy have been reported, although the durability of clinical effects is still under investigation. Overall, CAR NK cells are considered promising for their safety and effectiveness in treating hematological malignancies.14678
Is NKX019 a promising treatment for B-cell cancers?
Yes, NKX019, which uses engineered natural killer (NK) cells to target cancer cells, shows promise as a treatment for B-cell cancers. It can effectively attack cancer cells that are usually resistant to natural killer cells, offering a safer alternative to other therapies without severe side effects.23479
Eligibility Criteria
Adults with certain B-cell cancers like non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia that have come back or didn't respond to treatment can join. They must have had at least two prior treatments (one for some cases), be in fairly good health, and not pregnant. People with active brain cancer, recent other cancer treatments, or specific types of lymphoma aren't eligible.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- NKX019 (CAR T-cell Therapy)